FOLH1 and prostate cancer: Quantitative PET imaging is already used extensively in this field using Ga-68/Lu-177 peptides for diagnosis, staging, and treatment of somatostatin receptor tumours [3] and Ga-68/Lu-177 PSMA labels for the diagnosis, staging, and treatment of prostate cancer [4].